LB54640
Phase 2Small molecule
Rhythm PharmaceuticalsLB54640 is one of 13 small molecule programs targeting Genetic obesity. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in Hypothalamic Obesity
#DrugCompanyPhaseTrials
1Sandostatin
Sun PharmaApproved
Sandostatin LAR
NovartisApproved
Byetta
AstraZenecaPhase 3
Corlanor
AmgenPhase 3
Imcivree
Rhythm PharmaceuticalsPhase 3
Inderal
WWyeth-Lederle Vaccines
Phase 3
Proglycem
TevaPhase 2
Glucophage
EMD SeronoPhase 2
Syntocinon
SShana McCormack, MD
Phase 2
Pegvaliase
BioMarin PharmaceuticalPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LB54640. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company